---
layout: post
title: "金城医药2021年度预盈1.4亿至1.7亿元 同比扭亏"
date: 2022-01-11 18:18:47 +0800
categories: shanghaizhengquanbao·zhongguozhengquanwang
tags: 上海证券报·中国证券网新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.300233" data-code="300233|0|2" data-code2="300233|0|80|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.300233&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 300233_0" data-code="K 300233|0|2" data-code2="K 300233|0|80|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>金城医药披露业绩预告。公司预计2021年盈利14,000万元-17,000万元，上年同期为亏损48,884.48万元。业绩变动主要原因是上年业绩受计提商誉减值准备影响导致亏损。<br /></p><p class="em_media">（文章来源：上海证券报·中国证券网）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201112243907821>

[返回上海证券报·中国证券网新闻](//finews.withounder.com/category/shanghaizhengquanbao·zhongguozhengquanwang.html)｜[返回首页](//finews.withounder.com/)